Business Wire

Edge optimizes network performance with ADVA ALM fiber monitoring technology

Share

ADVA (FSE: ADV) today announced that Edge, a regional research and education (R&E) network based in New Jersey, has expanded its deployment of the ADVA ALM fiber monitoring solution to improve real-time service performance and reduce operating costs. The in-service assurance technology enables Edge to rapidly detect and locate faults in its optical transport infrastructure throughout New York, New Jersey and Pennsylvania. With more complete network visibility, Edge can respond in an instant to fiber issues and fix problems before services are affected. The ability to immediately identify areas of concern and precisely target maintenance efforts also helps reduce truck rolls and improves cost-efficiency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005463/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ADVA’s ALM helps Edge catch and resolve issues before they impact services. (Photo: Business Wire)

“As the Edge network and member base expands, we continuously strive to enhance our reliability and client experience. To do so, Edge has relied on ADVA technology for years and we count on leveraging their continued innovation to benefit our members. ADVA’s ALM assurance solution delivers real-time info on the quality of our fiber. It tells us exactly where repairs are needed, and that has proven to be a big help in terms of time and cost savings. In the past, we might know there was a problem causing intermittent disruption somewhere between New York and Philadelphia, for example. It could take days to find using traditional manual OTDR testing. Now we can react quickly and accurately, and there’s no more time wasted on site visits,” said a spokesperson for Edge. “The ALM lets us troubleshoot issues before they impact end users and deliver even more robust and efficient services, helping our customers advance research, education and economic development across the region.”

The ADVA ALM maximizes resource efficiency by providing comprehensive fiber health assurance. It now instantly alerts Edge to any fiber breaks or abnormal attenuation. The solution is also helping bolster network security by notifying maintenance teams of tapping attempts. The non-intrusive service-agnostic device identifies the exact geographic location of events through an intuitive graphical user interface. Featuring fanless operation and low-power consumption, the ultra-compact ALM enhances operational efficiency and sustainability across Edge’s infrastructure.

“The Edge network is a vital resource for the scientists, educators and healthcare providers they serve. We’re proud to support its team as they deliver even more to help organizations digitize their operations and achieve their strategic goals,” commented John Scherzinger, SVP of sales, Americas at ADVA. “Our ALM solution provides Edge with an intricate understanding of its optical fiber infrastructure. The tiny device has already had a big impact, helping the service provider diagnose and remedy issues while making maintenance easier and more environmentally friendly.”

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Edge
Founded in 2000, Edge, a 501(c)(3) nonprofit corporation, serves as a purpose-built research and education wide area network and technology solutions partner. Edge connects members with affordable, easy access to high-performance optical networking, commodity Internet and Internet2 services, and a variety of technology-powered products, solutions, and services. The Edge member consortium consists of colleges and universities, K-12 schools and districts, government entities, healthcare networks, and businesses spread throughout the continental US. The group is governed by the New Jersey Presidents’ Council with offices in Newark, Princeton, and Wall Township, NJ. For more information, please visit: www.njedge.net.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom